Loading...
  • synthesis
  • Brookhaven National Laboratory medical researchers Michiko Miura (left of chalkboard) and Peggy Micca (right of chalkboard) discuss the synthesis of boronated compounds with Marta Nawrocky (far left), from Psimei Pharmaceuticals Ltd. and Margaret Bogosian (seated, front) from Brookhaven Lab's Office of Intellectual Properties and Industrial Partnerships. (bnl.gov)
  • BNCT
  • Compared to BPA, the new boron compounds are expected to deliver higher concentrations of boron to certain tumors than to normal surrounding tissues within the neutron-irradiated regions, which may make the new compounds more effective for BNCT. (bnl.gov)
  • If pre-clinical studies under the CRADA agreement and subsequent clinical trials find the new compounds to be safe and effective, they may well be used in BNCT for the treatment of head and neck tumors and/or brain tumors. (bnl.gov)
  • The new boron compounds concentrate preferentially in tumors and destroy cancerous cells when they react with neutrons in BNCT. (bnl.gov)
  • In BNCT studies performed at Brookhaven reported in Radiation Research (April 2001), the new compound controlled 70 percent of leg tumors in mice, with little or no normal tissue damage or chemical toxicity to the animals. (bnl.gov)
  • normal tissues
  • Such imaging will allow physicians to view boron concentrations in a patient's tumors and in surrounding normal tissues, which will significantly aid in treatment planning. (bnl.gov)
  • tumor
  • Determine the boron concentration in the tumor, surrounding tissues, and blood of patients with operable thyroid cancer, squamous cell cancer of the head and neck, or liver metastases secondary to colorectal adenocarcinoma who receive boronophenylalanine-fructose complex (BPA-F) and/or sodium borocaptate (BSH) before surgical resection. (clinicaltrials.gov)
  • Determine the feasibility of using these drugs to obtain a favorable absolute boron-10 concentration in the tumor and optimal tumor-to-blood and tumor-to-healthy tissue boron-10 rates in these patients. (clinicaltrials.gov)
  • uptake
  • PURPOSE: This phase I trial is studying the side effects of giving BPA-F and/or BSH before surgery to detect boron uptake in tissues of patients with primary, metastatic, or recurrent thyroid cancer, head and neck cancer, or liver metastases from colorectal cancer. (clinicaltrials.gov)
  • Patent
  • BSA holds U.S. patents and U.S. patent applications covering these compounds and has filed international patent applications, which are pending. (bnl.gov)
  • Research
  • Upton, NY - The Department of Energy's Brookhaven National Laboratory and Psimei Pharmaceuticals Limited have signed a Cooperative Research and Development Agreement (CRADA) to develop Brookhaven-invented boron compounds for use in an experimental radiation therapy for cancer, as well as in other cancer treatments. (bnl.gov)